CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service Contract Development & Manufacturing Organization (CDMO) for the production of APIs, Drug Products, and associated Packaging Services. Through a growing network of focused investments across Europe and the US organized under Technology Platforms, CordenPharma experts translate complex processes, ideas and projects at any stage of development into high-value products.
Services
The wide breadth of CordenPharma technologies across all facilities have been organized into Technology Platforms to provide integrated full-service capabilities. CordenPharma Technology Platforms are supported by our global supply chain spanning the development of intermediates & APIs, formulation services and commercial cGMP manufacturing of APIs & Drug Products to packaging, clinical trial kit services, and pharma logistics.
The CordenPharma Peptides Platform is comprised of Bio-organic Peptide Active Pharmaceutical Ingredients (APIs). CordenPharma experts manufacture Peptide APIs using solid-phase, solution-phase, and hybrid solid-solution phase technology at all scales. The wide range of downstream processing capabilities, including preparative HPLC purification, benefits manufacturing at any stage of development.
Frank Haehner joined CordenPharma in 2016 as Managing Director, CordenPharma Plankstadt, (DE). He has more than 25 years of experience in the pharmaceutical industry in various executive roles.
Prior to joining CordenPharma Frank worked at Novartis, where he served as Head of Technology & Investment Portfolio Management, Head of Engineering Biologics, Technical Development and Manufacturing, as well as Project Director of BioInject, a new biopharmaceutical manufacturing facility.
Prior to joining CordenPharma Frank worked at Novartis, where he served as Head of Technology & Investment Portfolio Management, Head of Engineering Biologics, Technical Development and Manufacturing, as well as Project Director of BioInject, a new biopharmaceutical manufacturing facility.
CordenPharma's Highly Potent & Oncology Platform utilizes state-of-the-art high containment technology and processes to manufacture Highly Potent Active Pharmaceutical Ingredients (APIs) and Drug Products. CordenPharma provides expertise and reliability which is second to none in quality, delivery times and high Right-First-Time performance.
CordenPharma's Injectable manufacturing covers both Terminal Sterilization and Aseptic Filling Technologies for Pre-filled Syringes (PFS), Vials, Ampoules and Lyophilized Vials, with a wide range of filling volumes.
With multiple process and filling lines and an overall annual capacity of ~100 million units, the CordenPharma Injectable Platform offers the flexibility to support multiple programs and customers (>110 markets) in parallel, at any scale and stage of drug development.
With multiple process and filling lines and an overall annual capacity of ~100 million units, the CordenPharma Injectable Platform offers the flexibility to support multiple programs and customers (>110 markets) in parallel, at any scale and stage of drug development.
Reviews
Be the first to review Corden Pharma International.
Write a Review
